A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

计划入组 188 人 · 首次发布于 2026 年 7 月 14 日

Study on the Mechanism of lcn2 in Obesity

计划入组 500 人 · 首次发布于 2020 年 10 月 5 日

UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa

计划入组 70 人 · 首次发布于 2012 年 12 月 4 日

UCN2(Gubra)

GUB-002496

GUB-014295

HUB

Guy Steuer

Israel

Guy Waddell

United States

Gubra Advances Obesity Pipeline as AbbVie and Boehringer Ingelheim Programs Reach Phase 2

Gubra Expands Facilities by 70% to Support Growing Peptide Drug Pipeline and CRO Operations

Hanmi Pharmaceutical to Present Phase 1 Results of Next-Generation Obesity Drugs at ADA 2025